European Commission has invited more than 200 blood-collection services around the EU to apply for funding for the purchase of plasmapheresis equipment, i.e. equipment that takes plasma from donors. The aim of this action is to support the treatment of new COVID-19 patients who are fighting the disease, by increasing EU capacity to collect convalescent plasma, i.e. plasma from recovered COVID-19 patients. This action is part of the Emergency Support Instrument (ESI). Grants will be provided to public and NGO blood-collection services authorised to collect plasma.
This action demonstrates the Commission’s commitment to developing therapeutics, as specified in the EU health preparedness for possible future outbreaks communication.
Stella Kyriakides, Commissioner for Health and Food Safety, said: “Convalescent plasma could be a promising treatment for COVID-19.With the financing we put forward today, we are able to go a step further in plasma collection and I invite all relevant stakeholders to make use of it. We will continue to explore all possible options to support the development and access to safe and effective treatments for COVID-19 to protect our citizens. This remains our primary objective in the weeks and months ahead.”
The treatment consists of transfusing convalescent plasma to sick patients to boost their immunity and ability to fight the disease. Plasma transfusion is also used to purify antibodies to make a COVID-19 specific medicinal product (immunoglobin) as short-term alternative to vaccines. This product is given as a prophylactic injection to patients, vulnerable persons and healthcare workers, or as a treatment. The efficacy of these treatments is being investigated worldwide, including in an EU research project funded by Horizon 2020. Preliminary results are promising while results from full clinical trials are forthcoming.
These treatments rely on the collection of large quantities of convalescent plasma donated by recovered patients.
At the moment, almost 75% of plasma collected by public blood services and the Red Cross is done via donations of whole blood, from which the plasma is then separated. This is a much less efficient collection method compared with plasmapheresis – a bedside process where plasma is taken from the donor whilst the other blood components are returned to the donor. In case of plasmapheresis, donors can donate higher volumes of plasma at one time and can donate once every 2 weeks compared with once every 3-4 months for whole blood donors. Additionally, ‘super donors’ – donors whose plasma is particularly rich in antibodies – can be asked to give donations many times over a period of months.
The invitation is valid for a month, and has a budget of €40 million funded through the Emergency Support Instrument. The allocation of grants will be done according to the needs expressed by Member States’ blood-collection services
The budget will support the purchase of a number of plasmapheresis machines and associated equipment, including collection kits, storage facilities, the testing and characterisation of plasma and organisational programmes.
Adopted by the Council in April 2020, the Emergency Support Instrument (ESI) allows the EU to provide emergency support addressing the human and economic consequences of a crisis such as the ongoing pandemic.
The ESI supports Member States in their efforts to address the COVID-19 pandemic in a strategic and coordinated manner at European level.
In the health area, the ESI is already being used to help address Member States’ ongoing needs and to contribute to preparedness for future outbreaks and a possible second wave. In particular, the ESI is supporting the transport of essential goods, medical teams and patients and is financing a facility to procure essential medical products for stockpiling and/or distribution to Member States.
Under the procurement facility, a contract was signed on 28 July to secure doses of the therapeutic Remdesivir for around 30,000 patients across the EU. Some 10 million masks to protect healthcare workers have also been purchased and delivery through batches is on-going.
A significant part of the budget available under the ESI will be used to secure the production of vaccines in the EU and sufficient supplies for its Member States through Advance Purchase Agreements with vaccine producers, in line with the EU Vaccines Strategy.